CorMedix Inc.

AI Score

0

Unlock

11.22
0.10 (0.90%)
At close: Jan 14, 2025, 3:59 PM
11.40
1.60%
Pre-market Jan 15, 2025, 05:37 AM EST
undefined%
Bid 10.99
Market Cap 680.80M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -0.8
PE Ratio (ttm) -14.02
Forward PE n/a
Analyst Buy
Ask 11.5
Volume 753,639
Avg. Volume (20D) 1,253,977
Open 11.24
Previous Close 11.12
Day's Range 10.98 - 11.42
52-Week Range 2.89 - 13.85
Beta undefined

About CRMD

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical setting...

Industry Biotechnology
Sector Healthcare
IPO Date May 13, 2010
Employees 82
Stock Exchange NASDAQ
Ticker Symbol CRMD

Analyst Forecast

According to 6 analyst ratings, the average rating for CRMD stock is "Buy." The 12-month stock price forecast is $16, which is an increase of 42.60% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts

Next Earnings Release

CorMedix Inc. is scheduled to release its earnings on Mar 11, 2025, before market opens.
Analysts project revenue of $19.79M, reflecting a n/a YoY growth and earnings per share of 0.05, making a -119.23% decrease YoY.
1 week ago · Source
+29.89%
CorMedix shares are trading higher after the compa... Unlock content with Pro Subscription
3 weeks ago · Source
+9.24%
CoreMedix shares are trading higher after the company announced it will be added to the Nasdaq Biotechnology Index.